Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine

The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 outpatient setting.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news